Highlights VYNE Therapeutics Inc.

Equities

VYNE

US92941V3087

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2026-02-13 pm EST			5-day change	1st Jan Change
0.5700 ^USD	+2.33%		+1.86%	-1.74%

Dec. 17	VYNE Therapeutics Inc., Yarrow Bioscience, Inc. - M&A Call
Dec. 17	Yarrow Bioscience, Inc. entered into an Agreement and Plan of Merger and Reorganization to acquire VYNE Therapeutics Inc. in a reverse merger transaction.	CI

Highlights

Dec. 17	Yarrow Bioscience, Inc. entered into an Agreement and Plan of Merger and Reorganization to acquire VYNE Therapeutics Inc. in a reverse merger transaction.	CI
Nov. 06	VYNE Therapeutics Q3 net loss narrows, strategic review ongoing	RE
Nov. 06	VYNE Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
25-08-14	VYNE Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
25-07-02	VYNE Therapeutics Inc. Provides Program Update on Oral BET inhibitor VYN202	CI
25-04-25	VYNE Says FDA Halted Psoriasis Drug Trial After Signs of Toxicity Found; Shares Down Pre-Bell	MT
25-02-19	VYNE Therapeutics Inc. Initiates Phase 1B Trial of VYN202, a Novel BD2-Selective Oral BET Inhibitor, in Plaque Psoriasis	CI
24-12-23	VYNE Therapeutics Reports 'Positive' Phase 1a Results for VYN202 Inhibitor	MT
24-12-23	VYNE Therapeutics Inc. Therapeutics Reports Positive Top-Line Phase 1A MAD Data for VYN202, Its Novel BD2-Selective Bet Inhibitor	CI
24-11-07	Earnings Flash (VYNE) VYNE THERAPEUTICS Reports Q3 Revenue $121,000	MT
24-11-07	VYNE Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI
24-09-12	VYNE Therapeutics Announces Positive Phase 1A Sad Data for Vyn202, A Novel Bd2-Selective Bet Inhibitor	CI
24-08-14	Earnings Flash (VYNE) VYNE THERAPEUTICS Posts Q2 Revenue $198,000	MT
24-08-14	VYNE Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI
24-06-13	Vyne Therapeutics Announces Dosing of First Participants in Phase 1A Trial of Novel Bd2-Selective Bet Inhibitor Vyn202	CI
24-06-05	VYNE Therapeutics Inc. Announces Dosing of First Subject in Phase 2b Vitiligo Trial of Novel BET Inhibitor VYN201	CI
24-05-09	Earnings Flash (VYNE) VYNE THERAPEUTICS Posts Q1 Revenue $98,000	MT
24-05-09	VYNE Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
24-05-06	Vyne Therapeutics Announces FDA Clearance of IND Application for Vyn202, A Novel Bd2-Selective Bet Inhibitor	CI
24-02-29	VYNE Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
24-02-29	VYNE Therapeutics Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	CI
24-01-10	VYNE Therapeutics Inc. Announces Positive Biomarker Data from Successful Phase 1B Trial of VYN201 for the Treatment of Vitiligo	CI
23-10-30	VYNE Therapeutics Inc. Announces Positive Data from Phase 1b Trial for Novel Bet Inhibitor VYN201 in Patients with Nonsegmental Vitiligo	CI
23-08-14	Earnings Flash (VYNE) VYNE THERAPEUTICS Posts Q2 Revenue $135,000	MT
23-05-11	VYNE Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Highlights VYNE Therapeutics Inc.

Equities

VYNE

US92941V3087

Biotechnology & Medical Research

Highlights

Filters